MARKET

CYTH

CYTH

Cyclo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.74
-0.20
-3.37%
After Hours: 5.80 +0.06 +1.05% 18:45 01/20 EST
OPEN
5.98
PREV CLOSE
5.94
HIGH
6.18
LOW
5.60
VOLUME
357.60K
TURNOVER
--
52 WEEK HIGH
30.00
52 WEEK LOW
3.400
MARKET CAP
26.26M
P/E (TTM)
-82.9480
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Synthetic Biologics, Check-Cap leads healthcare gainers; Bionano Genomics, Mersana Therapeutics among major losers
Gainers: Synthetic Biologics (SYN) +149%, Check-Cap (CHEK) +59%, Jaguar Health (JAGX) +50%, Cyclo Therapeutics CYTH +36%, Zomedica (ZOM) +42%.Losers: Bionano Genomics BNGO -29%, Mersana Therapeutics (MRSN) -23%, Millendo Therapeutics (MLND) -18%, TransEnterix (TRXC) -17%, Hoth Therapeutics HOTH -12%.
Seekingalpha · 01/05 16:05
Mid-Morning Market Update: Markets Edge Higher; ISM Manufacturing PMI Jumps to 60.7
Following the market opening Tuesday, the Dow traded up 0.09% to 30,252.40 while the NASDAQ rose 0.36% to 12,744.18. The S&P also rose, gaining 0.21% to 3,708.42.
Benzinga · 01/05 15:27
CHU, CHL, FUBO and SKLZ among premarket gainers
Aileron Therapeutics (ALRN) +73%.Broadway Financial Corporation (BYFC) +55% after regulatory approvals for merger with CFBanc Corporation.Atlantic American Corporation (AAME) +43%.Marker Therapeutics (MRKR) +30% after FDA lifted the partial clinical hold on it's
Seekingalpha · 01/05 13:27
Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo in Patients with Niemann-Pick Disease Type C
Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of neurodegenerative diseases, including its lead candidate Trappsol® Cyclo™ for the treatment of Niemann...
Business Wire · 01/05 13:00
Cyclo Therapeutics Announces Closing of Underwriters Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering
Business Wire · 12/22/2020 19:30
Benzinga Pro's Top 5 Stocks To Watch Friday, Dec. 18, 2020: BBVA, MGNX, FDX, AMGN, CYTH
Today's 5 Stock Ideas:  Banco Bilbao Vizcaya Argentaria (BBVA) - A crypto exposure play. The company has been investing in Coinbase since 2015 and Coinbase recently filed for an IPO. Macrogenix
Benzinga · 12/18/2020 13:07
What Can We Learn About Cyclo Therapeutics' (NASDAQ:CYTH) CEO Compensation?
N. Fine has been the CEO of Cyclo Therapeutics, Inc. ( NASDAQ:CYTH ) since 2015, and this article will examine the...
Simply Wall St. · 12/12/2020 07:01
Cyclo Therapeutics on go with enrollment in late-stage study with lead asset
The FDA has signed-off Phase 3 trial evaluating Cyclo Therapeutics's ([[CTDH]] +8.0%) lead candidate Trappsol Cyclo (Hydroxypropyl-β-cyclodextrin), for the treatment of Niemann-Pick Disease Type C, a rare inherited disorder in which the body
Seekingalpha · 10/21/2020 15:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYTH. Analyze the recent business situations of Cyclo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYTH stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 2
Institutional Holdings: 400
% Owned: 0.01%
Shares Outstanding: 4.57M
TypeInstitutionsShares
Increased
0
0
New
1
300
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.19%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
Chairman/Chief Executive Officer/Director
Nathan Fine
Chief Financial Officer
Joshua Fine
Chief Operating Officer/Chief Scientific Officer/Director/IR Contact Officer
Jeffrey Tate
Executive Vice President
George Fails
Senior Vice President
Sharon Hrynkow
Lead Director/Independent Director
Markus Sieger
Director
William Shanahan
Director
C. E. Rick Strattan
Director
Randall Toig
Independent Director
F. Patrick Ostronic
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CYTH
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company. The Company develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. NPC is a fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional and other industries, primarily for use in diagnostics and specialty drugs. It serves chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors.
More

Webull offers kinds of Cyclo Therapeutics Inc stock information, including NASDAQ:CYTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTH stock methods without spending real money on the virtual paper trading platform.